comprehensive -WSS

comprehensive

author：comprehensive 2025-10-02 02:34:49 - browse：7174

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： How to fix the rural physician shortage in the U.S.

WSS

Kenai launches with $82 million for Parkinson’s stem cell therapy

How to address the problem of discarded donor organs

How to keep neuroscience’s past racism from being its future

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Grail spinoff by Illumina should end disastrous merger attempt

A Q&A with Aletha Maybank, AMA’s chief health equity officer

leisure time

comprehensive

focus

Virginia high school admissions case could be legal follow

What STAT readers think about the FDA and patient advocacy

Drug repurposing or repositioning? The language matters

SNAP should offer more nutrition education

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

SNAP should offer more nutrition education

Cancer drug shortages should be causing more outrage

HCA sued by state AG for quality issues at Mission Health

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Congress gives doctors Medicare pay bump

knowledge

SNAP should offer more nutrition education

How to keep neuroscience’s past racism from being its future

Carvykti CAR

SNAP should offer more nutrition education

Covid isolation guidance eased by the CDC

Virtual care provider acquires bankrupt Pear's prescription apps

focus

Wikipedia

leisure time

entertainment